CHMP var dog imødekommende over for idéen om at opdatere de MIC breakpoints, der er angivet i produktresuméets afsnit 5. 1, således at dette afsnit også inkluderer de kliniske MIC breakpoints, der er fastlagt af European Committee on Antimicrobial Susceptibility Testing (EUCAST), da disse breakpoints ikke kun vedrører de patogener, der optræder ved kompliceret pyelonefritis, men også almindelige urinpatogener, som findes i forbindelse med andre indikationer relateret til urinvejene.
However the CHMP welcomed the idea to update the MIC breakpoints in section 5.1 of the SPC to include the clinical MIC breakpoints as defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) in section 5.1 of the SPC as these breakpoints are not only related to the pathogens found in complicated pyelonephritis, but to common urinary pathogens found in other urinary indications.